BEING FAT SUCKS. Take it from me, who has been obese all my life. Being overweight accompanies many health risks like hypertension, cardiac arrest, stroke and some cancers in rare cases.
Then of course there’s Adult onset diabetes or Type-2 Diabetes Mellitus. It accounts for 90% of all the diagnosed diabetes cases with majority of people not being diagnosed till the later stages of their life resulting in various complications like kidney failure, heart diseases and lower limb amputations.
When we eat, carbohydrates in the food are broken down into glucose, the fuel that runs the cells in the body. Diabetes is a digestive complaint, arising when cells aren’t able to absorb the glucose from the blood stream due to lack of insulin or it’s insufficient use, resulting in their fatigue despite the high blood glucose levels. Insulin is produced by beta cells, in clusters of islets situated within the pancreas. If the body doesn’t process the blood glucose with the help of available insulin it leads to prediabetes, a condition where blood glucose levels or A1C levels are higher than normal but not high enough to be diagnosed as diabetes. This calls for better diagnostics and monitoring systems for pre diabetics along with better medication for diagnosed individuals.
In the past few years, diabetic care divisions of major players have shown a decrease in growth despite increasing no. of diabetic patients every year coupled with their expenditure. Many of them are trying out new paths to cover up their losses. Bearing an example of this, earlier this year, Novo Nordisk gave a presentation in Endocrine Society’s annual conference in Boston, showcasing 3 years’ worth of data on efficiency of Saxenda and Victoza, their own version of Liraglutide. Owing to the inseparable nature of Diabetes and Obesity, pharmaceutical companies are estimated to a make a killing from sales of similar kind of products that act on both ailments simultaneously with any serious side effects. It is evident by Novo Nordisk Annual revenue figures, which showcased Victoza as their flagship product. But the underlying problems in this strategy are devising such drugs and getting them approved by regulating bodies without any hiccups, like the recalling of FEN-PHEN due to perilous effects.
Alternatively, emerging companies are concentrating on bringing out new technologies and challenging the longstanding firms. This is evident in success rate of continuous glucose monitoring(CGM) systems. With CGM you can get a grip on your glucose levels, by observing them real-time and getting to know their highs or lows, resulting in a better health management. With the help of a subcutaneous sensor, measuring the A1C levels in tissue fluids the CGM system gives insights into how food, physical activity, medication and environment are effecting your blood glucose levels. Medtronic’s latest CGM systems can actually alert you before you reach the state of hyperglycemia. Their MiniMed Insulin pumps have built-in CGM so that you can take necessary action as soon as possible. DexCom is another relevantly new entrant into the market with its flagship product G5 Continuous Glucose Monitoring (CGM) system giving tough competition to the market leaders. It is used along with self-monitoring blood glucose (SMBG) tests (finger stick test).
Recently, US Food and Drug Administration (FDA) advisory panel has approved the Dexcom G5 Mobile continuous glucose monitoring (CGM) system to be used as a replacement for finger stick glucose monitoring in diabetic patients. They voted immensely in favor of its safety, efficacy and benefits vs risk implications. The vote on has echoed the fact that the technology has moved in a progressive direction noticeably in recent years. According to DiaTribe founder Kelly close, 69% of Dexcom users are already using the devices off-label to administer insulin. At least now DexCom would be able to document the usage procedure and present it to patients, which is forbidden till now.
This decision overturns the belief that CGM systems must be used as adjuvants to testing strips, and if developed to full potential they can take a swing at replacing the former in near future. Market Data Forecast’s analysts have prepared a detailed report listing the drivers and restraints of the diabetic care devices market and discussing in detail the dynamics of the overall market addressed in form of comprehensive strategic analyses, company profiles and many more. You can get a free sample here. Visit our site and subscribe to our newsletters for more revealing insights of healthcare industry to make you decisions well researched and more informed.